CLAIMS

1. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate represented by the formula S_P-**4**:



S_P-**4**

having XRPD 2θ-reflections (± 0.2°) at 6.1 and 12.7.

2. The crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 1 further having XRPD 2θ-reflections (± 0.2°) at 8.2, 10.4, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8, and 23.3.

3. The crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of claim 1 or 2 having XRPD 2θ-reflections (± 0.2°) at 6.08, 8.2, 10.38, 10.85, 12.17, 12.7, 13.73, 14.1, 15.91, 16.83, 17.17, 17.66, 17.95, 18.79, 19.1, 19.41, 19.8, 20.11, 20.82, 21.81, 22.03, 23.03, 23.26, 23.64, 23.89, and 24.73.

4. A composition comprising crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3.

5. A pharmaceutical composition comprising crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-

methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3 and a pharmaceutically acceptable medium.

6. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3 for use in the treatment of a hepatitis C virus infection.

7. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3 for use in the treatment of a hepatitis C virus infection in a human.

8. A pharmaceutical composition comprising crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3, and another antiviral agent.

9. The pharmaceutical composition of claim 8, wherein the another antiviral agent is an HCV NS3 inhibitor.

10. The pharmaceutical composition of claim 8, wherein the another antiviral agent is an HCV NS5A inhibitor.

11. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3 for use in the treatment of a hepatitis C virus infection in combination with another antiviral agent.

12. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-

yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3 for use in the treatment of a hepatitis C virus infection in combination with another antiviral agent, wherein the another antiviral agent is an HCV NS3 inhibitor.

13. Crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3 for use in the treatment of a hepatitis C virus infection in combination with another antiviral agent, wherein the another antiviral agent is an HCV NS5A inhibitor.

14. A tablet comprising Sp-4:



S_P-**4**

,

wherein at least 70% of the Sp-4 is a crystalline Sp-4 having XRPD 2θ-reflections (±0.2°) at 6.1 and 12.7.

15. The tablet according to claim 14 wherein at least 80% of the Sp-4 is a crystalline Sp-4 having XRPD 2θ-reflections (±0.2°) at 6.1 and 12.7.

16. The tablet according to claim 14 or 15 wherein at least 90% of the Sp-4 is a crystalline Sp-4 having XRPD 2θ-reflections (±0.2°) at 6.1 and 12.7.

17. The tablet according to any one of claims 14-16 wherein the crystalline Sp-4 further has XRPD 2θ-reflections (±0.2°) at 8.2, 10.4, 17.2, 17.7, 18.0, 18.8, 19.4, 19.8, 20.1, 20.8, 21.8 and 23.3.

18. A tablet according to any one of claims 14 to 17 for use in the treatment of a hepatitis C virus infection.

19. A tablet according to any one of claims 14 to 17 and at least one other antiviral agent for use in the treatment of a hepatitis C virus infection.

20. A tablet according to claim 19, wherein the other antiviral agent is a HCV NS3 protease inhibitor.

21. A tablet according to claim 19, wherein the other antiviral agent is a HCV NS5A inhibitor.

22. A tablet according to claim 19, wherein the other antiviral agent is a HCV NS3 protease inhibitor and a HCV NS5A inhibitor.

23. Use of crystalline (S)-isopropyl 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate of any one of claims 1-3 in the preparation of a medicament for the treatment of a hepatitis C virus infection.

24. Use according to claim 23 wherein the medicament further comprises at least one other antiviral agent.

25. Use according to claim 24 wherein the other antiviral agent is one or more of a HCV NS3 protease inhibitor and a HCV NS5A inhibitor.